Keros Therapeutics reports Q1 EPS $3.62

Reports Q1 revenue $211.25M. Keros reported a net income of $148.5M in the first quarter as compared to a net loss of $43.1M in the first quarter of 2024. The increase of $191.6M was largely due to revenue recognized related to Keros’ license agreement with Takeda, partially offset by increased research and development efforts as well as additional investments to support the achievement of Keros’ clinical and corporate goals. “In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim of advancing KER-065 to a Phase 2 clinical trial in the first quarter of 2026,” said Jasbir Seehra, Chair and Chief Executive Officer. “As our Board of Directors continues its review process to evaluate strategic alternatives to enhance stockholder value for the Company, we remain focused on the execution of our strategy and advancing the development of our pipeline of novel therapeutics. We expect to report data in the second quarter of 2025 from the Phase 2 TROPOS trial evaluating cibotercept (KER-012) in patients with pulmonary arterial hypertension and we plan to evaluate the appropriate development strategy for cibotercept following that data readout.”